On July 22, 2026 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, reported that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the Canaccord Genuity’s 46th Annual Growth Conference taking place in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Canaccord Genuity 46th Annual Growth Conference

Date:

Wednesday, August 12, 2026

Time:

12:30pm ET

To register and view the presentation, please CLICK HERE.

(Press release, TuHURA Biosciences, JUL 22, 2026, View Source [SID1234669373])